Citations

Clear

912 citation(s) found for "Yu, Caroline".

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
West, Diana C., Kocherginsky, Masha , Tonsing-Carter, Eva , Dolcen, Deniz Nesli , Hosfield, David J., Lastra, Ricardo R. , Sinnwell, Jason P. , Bowie, Kathleen R. , Skor, Maxwell N., Pierce, Charles F., Styke, Sarah C., Kim, Caroline R. , Wet, Larischa de, Wang, Liewei , Győrffy, Balázs , Conzen, Suzanne D. , Thompson, Kevin J. , Greene, Geoffrey L , Sinnwell, Jason P , Harkless, Ryan V. , Boughey, Judy C. , Goetz, Matthew P. , Kalari, Krishna R. , Fleming, Gini F. , Győrffy, Balázs

Mayo Clinic

Clinical Cancer Research | April 10, 2018 | Volume: 24 | Issue: 14 | Pages: 3433-3446

10.1158/1078-0432.ccr-17-2793 | PMID 29636357 Get It

Abstract Purpose: Although high glucocorticoid receptor (GR) expression in early-stage estrogen receptor (ER)-negative breast cancer is associated with shortened relapse-free survival (RFS), how associated GR transcriptional activity contributes to aggressive breast cancer behavior is not well understood. Using potent GR antagonists and primary tumor gene expression data, we sought to identify a tumor-relevant gene signature based on GR activity that would be more predictive than GR expression alone. Experimental Design: Global gene expression and GR ChIP-sequencing were performed to identify GR-regulated genes inhibited by two chemically distinct GR antagonists, mifepristone and CORT108297. Differentially expressed genes from MDA-MB-231 cells were cross-evaluated with significantly expressed genes in GR-high versus GR-low ER-negative primary breast cancers. The resulting subset of GR-targeted genes was analyzed in two independent ER-negative breast cancer cohorts to derive and then validate the GR activity signature (GRsig). Results: Gene expression pathway analysis of glucocorticoid-regulated genes (inhibited by GR antagonism) revealed cell survival and invasion functions. GR ChIP-seq analysis demonstrated that GR antagonists decreased GR chromatin association for a subset of genes. A GRsig that comprised n = 74 GR activation-associated genes (also reversed by GR antagonists) was derived from an adjuvant chemotherapy-treated Discovery cohort and found to predict probability of relapse in a separate Validation cohort (HR = 1.9; P = 0.012). Conclusions: The GRsig discovered herein identifies high-risk ER-negative/GR-positive breast cancers most likely to relapse despite administration of adjuvant chemotherapy. Because GR antagonism can reverse expression of these genes, we propose that addition of a GR antagonist to chemotherapy may improve outcome for these high-risk patients. Clin Cancer Res; 24(14); 3433–46. ©2018 AACR.
Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers
Meeter, Lieke , Sias, Ana C. , Jiskoot, Lize C. , Kaat, Laura Donker , Papma, Janne M., Panman, Jessica , Ende, Emma L. van der , Dopper, Elise G.P. , Graff, Caroline , Boxer, Adam L. , Rosen, Howard J., Sánchez‐Valle, Raquel , Galimberti, Daniela , Pijnenburg, Yolande A.L. , Benussi, Luisa , Ghidoni, Roberta , Borroni, Barbara , Laforce, Robert , Campo, Marta del , Teunissen, Charlotte E. , Minkelen, Rick van , Coppola, Giovanni , Geschwind, Dan, Rademakers, Rosa , Karydas, Anna M., Öijerstedt, Linn , Binetti, Giuliano , Padovani, Alessandro , Cash, David M. , Dick, Katrina M., Bocchetta, Martina , Rohrer, Jonathan D. , Petrucelli, Leonard , Lee, Suzee E. , Gendron, Tania F. , Del Campo, Marta , Teunissen, Charlotte E , Sánchez-Valle, Raquel , Rohrer, Jonathan D , Russo, Silvia P. , Papma, Janne M. , Franzen, Sanne , Rojas, Julio C. , Scarpini, Elio , Miller, Bruce L. , Swieten, John C. van , Padovani, Alessandro , Cash, David M , Donker Kaat, Laura , Dopper, Elise G P , Galimberti, Daniela , Bocchetta, Martina , Pijnenburg, Yolande A L , Jiskoot, Lize C , Laforce, Robert , Graff, Caroline , Borroni, Barbara

Mayo Clinic

Annals of Clinical and Translational Neurology | April 10, 2018 | Volume: 5 | Issue: 5 | Pages: 583-597

10.1002/acn3.559 | PMID 29761121 Get It

AbstractObjectiveTo evaluate poly(GP), a dipeptide repeat protein, and neurofilament light chain (NfL) as biomarkers in presymptomatic C9orf72 repeat expansion carriers and patients with C9orf72‐associated frontotemporal dementia. Additionally, to investigate the relationship of poly(GP) with indicators of neurodegeneration as measured by NfL and grey matter volume.MethodsWe measured poly(GP) and NfL levels in cerebrospinal fluid (CSF) from 25 presymptomatic C9orf72 expansion carriers, 64 symptomatic expansion carriers with dementia, and 12 noncarriers. We explored associations with grey matter volumes using region of interest and voxel‐wise analyses.ResultsPoly(GP) was present in C9orf72 expansion carriers and absent in noncarriers (specificity 100%, sensitivity 97%). Presymptomatic carriers had lower poly(GP) levels than symptomatic carriers. NfL levels were higher in symptomatic carriers than in presymptomatic carriers and healthy noncarriers. NfL was highest in patients with concomitant motor neuron disease, and correlated with disease severity and survival. Associations between poly(GP) levels and small grey matter regions emerged but did not survive multiple comparison correction, while higher NfL levels were associated with atrophy in frontotemporoparietal cortices and the thalamus.InterpretationThis study of C9orf72 expansion carriers reveals that: (1) poly(GP) levels discriminate presymptomatic and symptomatic expansion carriers from noncarriers, but are not associated with indicators of neurodegeneration; and (2) NfL levels are associated with grey matter atrophy, disease severity, and shorter survival. Together, poly(GP) and NfL show promise as complementary biomarkers for clinical trials for C9orf72‐associated frontotemporal dementia, with poly(GP) as a potential marker for target engagement and NfL as a marker of disease activity and progression.
Telemedicine Use for Movement Disorders: A Global Survey
Hassan, Anhar , Dorsey, E. Ray , Bloem, Bastiaan R. , Guttman, Mark, Pantelyat, Alexander , Galifianakis, Nicholas B. , Bajwa, Jawad A. , Gatto, Emilia , Cubo, Esther , Pantelyat, Alex , Goetz, Christopher G. , Tanner, Caroline M. , Mari, Zoltan K.

Mayo Clinic

Telemedicine and e-Health | March 22, 2018 | Volume: 24 | Issue: 12 | Pages: 979-992

10.1089/tmj.2017.0295 | PMID 29565764 Get It

Background: Telemedicine is increasingly used to care for patients with movement disorders, but data regarding its global use are limited. Introduction: To obtain baseline international data about telemedicine use among movement disorder clinicians. Methods: An online survey was sent to all 6,056 Movement Disorder Society members in 2015. Scope, reimbursement, and perceived quality of telemedicine were assessed. Results: There were 549 respondents (9.1% overall response rate) from 83 countries. Most (85.8%) were physicians, and most (70.9%) worked in an academic or university practice. Half of respondents ( n = 287, from 57 countries) used telemedicine for clinical care; activities included e-mail (63.2%), video visits (follow-up [39.7%] and new [35.2%]), and video-based education (35.2%). One hundred five respondents personally conducted video visits, most frequently to outpatient clinics (53.5%), patient homes (30.8%), and hospital inpatients (30.3%). The most common challenges were a limited neurological examination (58.9%) and technological difficulties (53.3%), and the most common benefits were reduced travel time (92.9%) and patient costs (60.1%). The most frequent reimbursements were none (39.0%), public insurance (24.5%), and patient payment (9.3%). Half of respondents planned to use telemedicine in the future, and three-quarters were interested in telemedicine education. Conclusions: More than 250 respondents around the world engage in telemedicine for movement disorders; most perceived benefit for patients, despite challenges and reimbursement for clinicians. Formal instruction on telemedicine is highly desired. Although the survey response was low and possibly biased to over represent those with telemedicine experience, the study provides baseline data for future comparison and to improve telemedicine delivery.
Bone vascularized composite allotransplantation model in swine tibial defect: Evaluation of surgical angiogenesis and transplant viability
Kotsougiani, Dimitra , Hundepool, Caroline A. , Bulstra, Liselotte F. , Friedrich, Patricia F. , Shin, Alexander Y. , Bishop, Allen T.

Mayo Clinic

Microsurgery | March 5, 2018 | Volume: 39 | Issue: 2 | Pages: 160-166

10.1002/micr.30310 | PMID 29504151 Get It

IntroductionIn prior small animal studies, we maintained vascularized bone allotransplant viability without long‐term immunotherapy. Instead, an autogenous neoangiogenic circulation is created from implanted vessels, sufficient to maintain bone viability with only 2 weeks immunosupression. Blood flow is maintained despite rejection of the allogeneic vascular pedicle thereafter. We have previously described a large animal (swine) pre‐clinical model, reconstructing tibial defects with vascularized tibial allotransplants. In this manuscript, autologous angiogenesis is evaluated in this model and correlated with bone viability.Materials and methodsAllogeneic tibial segments were transplanted across a major swine leukocyte antigen mismatch. Microvascular repair of the bone VCA pedicle was combined with intraosseous implantation of an autogenous arteriovenous (AV) bundle. The bundle was ligated in group 1 (n = 4), and allowed to perfuse in group 2 (n = 4). Three‐drug immunotherapy was given for 2 weeks. At 16 weeks micro‐CT angiography quantified neoangiogenic vessel volume. Bone viability, rejection grade, and bone healing were analyzed.ResultsA substantial neoangiogenic circulation developed from the implanted AV‐bundle in group 2, with vessel density superior to ligated AV‐bundle controls (0.11 ± 0.05 vs. 0.01 ± 0.01, P = .029). Bone allotransplant viability was also significantly enhanced by neoangiogenesis (78.7 ± 4.4% vs. 27.7 ± 5.8%, P = .028) with higher bone healing scores (21.4 ± 2.9 vs. 12.5 ± 3.7, P = .029). Ligated control tibias demonstrated disorganized bone morphology and higher local inflammation (P = .143).ConclusionImplantation of autogenous AV bundles into vascularized bone allotransplants resulted in the rapid formation of a neoangiogenic autogenous blood supply in a swine tibia model that maintained bone viability, improved bone healing, and minimized rejection.
Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation
Abubakar, Mustapha , Chang‐Claude, Jenny , Ali, H. Raza , Chatterjee, Nilanjan , Coulson, Penny , Daley, Frances , Blows, Fiona M., Benı́tez, Javier , Brenner, Hermann , Stegmaier, Christa, Mannermaa, Arto, Sinn, Hans‐Peter , Tollenaar, Rob A.�E.�M. , Seynaeve, Caroline, Figueroa, Jonine D. , Lissowska, Jolanta , Hewitt, Stephen M. , Hooning, Maartje J. , Foekens, Renée , Koppert, Linetta B. , Investigators, kConFab, Bolla, Manjeet K. , Wang, Qin , Jones, Michael E. , Schoemaker, Minouk J. , Keeman, Renske , Easton, Douglas F. , Swerdlow, Anthony J. , García‐Closas, Montserrat , Swerdlow, Anthony J , Lissowska, Jolanta , Sinn, Peter , Jones, Michael E , Brenner, Hermann , García-Closas, Montserrat , Benitez, Javier , Figueroa, Jonine D , Milne, Roger L. , Mannermaa, Arto, Rudolph, Anja , Couch, Fergus J. , Devilee, Peter , Hollestelle, Antoinette , Sherman, Mark E. , Schmidt, Marjanka K. , Pharoah, Paul D.P. , Schoemaker, Minouk J

Mayo Clinic

International Journal of Cancer | March 1, 2018 | Volume: 143 | Issue: 4 | Pages: 746-757

10.1002/ijc.31352 | PMID 29492969 Get It

Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p‐values for case–case and case–control comparisons for risk factors in relation to levels of grade and quartiles (Q1–Q4) of KI67 were estimated using polytomous logistic regression models. Case–case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1 = 1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1 = 1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1 = 0.27 (0.16, 0.44)] tumors. In case–control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.
Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model
Germany, Caroline E., Reker, Ashlie N., Hinton, David J., Oliveros, Alfredo , Shen, Xinggui , Andres‐Beck, Lindsey G., Wininger, Katheryn M. , Cvek, Urška , Nam, Hyung Wook , Nam, Hyung W , Trutschl, Marjan , Choi, Doo‐Sup

Mayo Clinic

PROTEOMICS | February 13, 2018 | Volume: 18 | Issue: 7 | Pages: No page available

10.1002/pmic.201700417 | PMID 29437267 Get It

AbstractAcamprosate is an FDA‐approved medication for the treatment of alcoholism that is unfortunately only effective in certain patients. Although acamprosate is known to stabilize the hyper‐glutamatergic state in alcoholism, pharmacological mechanisms of action in brain tissue remains unknown. To investigate the mechanism of acamprosate efficacy, the authors employ a pharmacoproteomics approach using an animal model of alcoholism, type 1 equilibrative nucleoside transporter (ENT1) null mice. The results demonstrate that acamprosate treatment significantly decreased both ethanol drinking and preference in ENT1 null mice compared to that of wild‐type mice. Then, to elucidate acamprosate efficacy mechanism in ENT1 null mice, the authors utilize label‐free quantification proteomics comparing both genotype and acamprosate treatment effects in the nucleus accumbens (NAc). A total of 1040 protein expression changes are identified in the NAc among 3634 total proteins detected. The proteomics and Western blot result demonstrate that acamprosate treatment decreased EAAT expression implicating stabilization of the hyper‐glutamatergic condition in ENT1 null mice. Pathway analysis suggests that acamprosate treatment in ENT1 null mice seems to rescue glutamate toxicity through restoring of RTN4 and NF‐κB medicated neuroimmune signaling compared to wild‐type mice. Overall, pharmacoproteomics approaches suggest that neuroimmune restoration is a potential efficacy mechanism in the acamprosate treatment of certain sub‐populations of alcohol dependent subjects.
Immunotherapy‐Induced Colitis: An Emerging Problem for the Hospitalist
Marin‐Acevedo, Julian A. , Burton, M. Caroline , Harris, Dana M.

Mayo Clinic

Journal of Hospital Medicine | February 7, 2018 | Volume: 13 | Issue: 6 | Pages: 413-418

10.12788/jhm.2925 | PMID 29419822 Get It

Since their introduction for melanoma treatment, the use of immune checkpoint inhibitors (ICIs) has rapidly expanded. Though their impact on survival is irrefutable, these medications have been associated with autoimmune‐like adverse events related to their ability to induce the immune system. One of the most commonly affected organ systems is the gastrointestinal (GI) tract, in which manifestations range from mild diarrhea to severe colitis with intestinal perforation. Because of the increased use of ICIs, hospitalists are caring for an increasing number of patients experiencing their adverse events. We present a case‐oriented review of the GI adverse events associated with the use of ICIs to familiarize the hospitalist with their mechanism of action and potential complications and to emphasize the importance of early diagnosis and treatment to decrease morbidity and mortality.
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
Fahn, Stanley, Espay, Alberto J. , Trenkwalder, Claudia , Adler, Charles H. , Patni, Rajiv, Johnson, Reed, Espay, Alberto J , Adler, C H , Isaacson, Stuart , Pahwa, Rajesh , Tanner, Caroline M.

Mayo Clinic

Movement Disorders Clinical Practice | February 5, 2018 | Volume: 5 | Issue: 2 | Pages: 183-190

10.1002/mdc3.12595 | PMID 29780852 Get It

AbstractBackgroundADS‐5102 (amantadine) extended release capsules (GOCOVRI™) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS‐5102 reduced dyskinesia and OFF time in phase 3 controlled trials of up to six months. Amantadine immediate release (IR) is used for dyskinesia, but suboptimal durability and tolerability limit its clinical utility.MethodsIn an ongoing, open‐label, phase 3 study in the US and Western Europe (NCT02202551), patients with PD received 274 mg of ADS‐5102 (equivalent to 340 mg amantadine HCl) once daily at bedtime for up to two years. Study outcomes included safety and assessment of motor complications, as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) Part IV. This manuscript focuses on those patients switched to ADS‐5102 from amantadine IR. Results in two groups of patients who previously completed a randomized controlled trial (EASE LID or EASE LID 3) are also presented according to use of ADS‐5102 or placebo in that study before enrollment in the open‐label study.ResultsChange in MDS‐UPDRS Part IV at week 8 was –0.3 in the previous ADS‐5102 subgroup (n = 61), –3.4 in the previous placebo subgroup (n = 79), and –3.4 in the previous amantadine IR subgroup (n = 32). Effects were maintained to week 64. In the previous amantadine IR subgroup (mean treatment duration, 2.5 years), mean amantadine IR dose was 221 mg. Safety data were consistent with previous randomized controlled trials of ADS‐5102.ConclusionThese open‐label data suggest ADS‐5102 provides incremental reduction from baseline in MDS‐UDPRS Part IV score in patients switched directly from amantadine IR, without exacerbating adverse events.
Noninvasive optical spectroscopy for identification of non‐melanoma skin cancer: Pilot study
Carpenter, David , Sajisevi, Mirabelle , Chapurin, Nikita , Brown, C. Scott , Cheng, Tracy , Palmer, Gregory M. , Stevenson, Daniel, Rao, Caroline L., Hall, Russell P. , Woodard, Charles R., Sajisevi, Mirabelle B

Mayo Clinic

Lasers in Surgery and Medicine | January 13, 2018 | Volume: 50 | Issue: 3 | Pages: 246-252

10.1002/lsm.22786 | PMID 29331035 Get It

ObjectiveOptical spectroscopy offers a noninvasive alternative to biopsy as a first‐line screening tool for suspicious skin lesions. This study sought to define several optical parameters across malignant and benign tissue types.Study DesignProspective pilot trial utilizing the Zenalux IM1 optical spectroscopy device from April 2016 to February 2017. For each skin lesion, provider pre‐biopsy probability of malignancy was compared to histolopathologic diagnosis. Optical data were characterized across basal cell carcinoma (BCC; n = 9), squamous cell carcinoma (SCC; n = 5), actinic keratosis (AK; n = 4), scar tissue (n = 6), nevus (n = 2), and neurofibroma (NF; n = 1). Across all patients, agreement was determined between control measurements collected adjacent to the lesion and from the upper extremity.MethodsProspective single center pilot study. The optical properties of 27 cutaneous lesions were collected from 18 adult patients presenting to Otolaryngology and Dermatology clinics with suspicious skin lesions warranting biopsy. Spectroscopy measurements were recorded for each lesion: two at the lesion site, two at an adjacent site (internal control), and one at the central medial upper extremity (arm control). Variables of interest included absolute oxygenated hemoglobin (Hb), Hb saturation, total Hb concentration, and Eumelanin concentration. For each lesion, internal control averages were subtracted from lesion averages to provide delta parameter values, and lesion averages were divided by internal control averages to provide ratio parameter values.ResultsMean percent difference between pre‐biopsy probability of malignancy and histology was 29%, with a difference of 75% or greater seen in 5 of 25 lesions. Mean values for BCC, SCC, AK, and scar tissue varied most between extracted mean reduced scatter estimate (; cm−) delta values (BCC: −2.2 ± 3.8; SCC: −3.9 ± 2.0; AK: −3.3 ± 4.2, Scar: −1.7 ± 1.2) and total Hb (µM) ratio (BCC: 2.0 ± 3.3; SCC: 3.0 ± 1.3; AK: 1.1 ± 0.6; Scar: 1.4 ± 1.1). Agreement between local and arm controls was poor.ConclusionThis pilot trial utilizes optical spectroscopy as a noninvasive method for determining cutaneous lesion histology. Effect sizes observed across optical parameters for benign and malignant tissue types will guide larger prospective studies that may ultimately lead to prediction of lesional histology without need for invasive biopsy. Lasers Surg. Med. 50:246–252, 2018. © 2018 Wiley Periodicals, Inc.
The 2017 Cervical Spine Research Society International Traveling Fellowship
Scemama, Caroline, Tornero, Eduardo, Mesfin, Addisu , Zhou, Feifei , Kaito, Takashi , Nassr, Ahmad

Mayo Clinic

Spine | December 13, 2017 | Volume: 43 | Issue: 4 | Pages: 235-238

10.1097/brs.0000000000002523 | PMID 29239907 Get It